The role of urotensin II in the metabolic syndrome

Peptides

Volumn 29, Issue 5, 2008, Pages 859-867

  Ong, Kwok Leung ^a   Wong, Louisa Y F ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Diabetes; Hypertension; Inflammation; Metabolic syndrome; Urotensin II; Vasoactive peptide

Indexed keywords

ACT 058362; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; NEUROPEPTIDE RECEPTOR; PALOSURAN; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RECEPTOR;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CIGARETTE SMOKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; EXERCISE; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOZOCIN DIABETES; VASOCONSTRICTION;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; UROTENSINS;

MUS;

EID: 42149115655     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.06.003     Document Type: Article

References (108)

1. Actelion-Other Projects in Clinical Development. Available at: http://www.actelion.com/uninet/www/www_main_p.nsf/Content/Other+Projects +in+Clinical+Development, Accessed 23 February 2007.
2. Affolter J.T., Newby D.E., Wilkinson I.B., Winter M.J., Balment R.J., and Webb D.J. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 54 (2002) 617-621
3. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
4. Alessi M.C., and Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 26 (2006) 2200-2207
5. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
6. Baron A.D. Insulin resistance and vascular function. J Diabetes Complications 16 (2002) 92-102
7. Behm D.J., Doe C.P., Johns D.G., Maniscalco K., Stankus G.P., Wibberley A., et al. Urotensin-II: a novel systemic hypertensive factor in the cat. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 274-280
8. Bern H.A., Pearson D., Larson B.A., and Nishioka R.S. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal necrosecretory system in fishes. Recent Prog Horm Res 41 (1985) 533-552
9. Birker-Robaczewska M., Boukhadra C., Studer R., Mueller C., Binkert C., and Nayler O. The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma. J Recept Signal Transduct Res 23 (2003) 289-305
10. Bohm F., and Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 135 (2002) 25-27
11. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
12. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 (2004) 117-123
13. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
14. Camarda V., Rizzi A., Calo G., Gendron G., Perron S.I., Kostenis E., et al. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 365 (2002) 141-149
15. Cameron N.E., Eaton S.E., Cotter M.A., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 (2001) 1973-1988
16. Charles C.J., Rademaker M.T., Richards A.M., and Yandle T.G. Urotensin II: evidence for cardiac, hepatic and renal production. Peptides 26 (2005) 2211-2214
17. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
18. Church T.S., Barlow C.E., Earnest C.P., Kampert J.B., Priest E.L., and Blair S.N. Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 22 (2002) 1869-1876
19. Clozel M., Binkert C., Birker-Robaczewska M., Boukhadra C., Ding S.S., Fischli W., et al. Pharmacology of the Urotensin-II receptor antagonist Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-y l)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 311 (2004) 204-212
20. Clozel M., Hess P., Qiu C., Ding S.S., and Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 316 (2006) 1115-1121
21. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
22. Cybulsky M.I., and Gimbrone M.A.J. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251 (1991) 788-791
23. Dabek J., Kulach A., Monastyrska-Cup B., and Gasior Z. Transforming growth factor beta and cardiovascular diseases: the other facet of the 'protective cytokine'. Pharmacol Rep 58 (2006) 799-805
24. Dai H.Y., Kang W.Q., Wang X., Yu X.J., Li Z.H., Tang M.X., et al. The involvement of transforming growth factor-beta1 secretion in Urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul Pept 140 (2007) 88-93
25. Djordjevic T., BelAiba R.S., Bonello S., Pfeilschifter J., Hess J., and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25 (2005) 519-525
26. Do-Rego J.C., Chatenet D., Orta M.H., Naudin B., Le Cudennec C., Leprince J., et al. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology (Berl) 183 (2005) 103-117
27. Douglas S.A., Ashton D.J., Sauermelch C.F., Coatney R.W., Ohlstein D.H., Ruffolo M.R., et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36 (2000) S163-S166
28. Douglas S.A., Sulpizio A.C., Piercy V., Sarau H.M., Ames R.S., Aiyar N.V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 (2000) 1262-1274
29. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
30. Du W., Sun H., Wang H., Qiang B., Shen Y., Yao Z., et al. Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes. Chin Med J 114 (2001) 876-878
31. El-Atat F.A., Stas S.N., McFarlane S.I., and Sowers J.R. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 15 (2004) 2816-2827
32. Ernst E., and Resch K.L. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118 (1993) 956-963
33. Fernandez-Real J.M., and Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 24 (2003) 278-301
34. Gardiner S.M., March J.E., Kemp P.A., Davenport A.P., and Bennett T. Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 132 (2001) 1625-1629
35. Gartlon J., Parker F., Harrison D.C., Douglas S.A., Ashmeade T.E., Riley G.J., et al. Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berl) 155 (2001) 426-433
36. Gilbert R.E., and Cooper M.E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. Kidney Int 56 (1999) 1627-1637
37. Gold S.J., Thompson J.P., Williams J.P., Helm E.E., Sadler J., Song W., et al. Does cigarette smoking increase plasma urotensin II concentrations?. Eur J Clin Pharmacol 63 (2007) 253-257
38. American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
39. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
40. Gruson D., Rousseau M.F., Ahn S.A., van Linden F., and Ketelslegers J.M. Circulating urotensin II levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers. Peptides 27 (2006) 1527-1531
41. Guerre-Millo M. Adipose tissue and adipokines: for better or worse. Diabetes Metab 30 (2004) 13-19
42. Heller J., Schepke M., Neef M., Woitas R., Rabe C., and Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J Hepatol 37 (2002) 767-772
43. Heringlake M., Kox T., Uzun O., Will B., Bahlmann L., Klaus S., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 (2004) 129-136
44. Hillier C., Berry C., Petrie M.C., O'Dwyer P.J., Hamilton C., Brown A., et al. Effects of urotensin II in human arteries and veins of varying caliber. Circulation 103 (2001) 1378-1381
45. Hood S.G., Watson A.M., and May C.N. Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade. Peptides 26 (2005) 1248-1256
46. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 104 (2001) 2996-3007
47. Imperatore G., Riccardi G., Iovine C., Rivellese A.A., and Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study. Diabetes Care 21 (1998) 649-654
48. Ishihata A., Sakai M., and Katano Y. Vascular contractile effect of urotensin II in young and aged rats: influence of aging and contribution of endothelial nitric oxide. Peptides 27 (2006) 80-86
49. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
50. Joyal D., Huynh T., Aiyar N., Guida B., Douglas S., and Giaid A. Urotensin-II levels in acute coronary syndromes. Int J Cardiol 108 (2006) 31-35
51. Kent Jr. J.W., Comuzzie A.G., Mahaney M.C., Almasy L., Rainwater D.L., VandeBerg J.L., et al. Intercellular adhesion molecule-1 concentration is genetically correlated with insulin resistance, obesity, and HDL concentration in Mexican Americans. Diabetes 53 (2004) 2691-2695
52. Khan S.Q., Bhandari S.S., Quinn P., Davies J.E., and Ng L.L. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 117 (2007) 323-328
53. Kiowski W., Linder L., Stoschitzky K., Pfisterer M., Burckhardt D., Burkart F., et al. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 90 (1994) 27-34
54. Langham R.G., Kelly D.J., Gow R.M., Zhang Y., Dowling J.K., Thomson N.M., et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 44 (2004) 826-831
55. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
56. Lekakis J., Papamichael C., Vemmos C., Nanas J., Kontoyannis D., Stamatelopoulos S., et al. Effect of acute cigarette smoking on endothelium-dependent brachial artery dilatation in healthy individuals. Am J Cardiol 79 (1997) 529-531
57. Lim M., Honisett S., Sparkes C.D., Komesaroff P., Kompa A., and Krum H. Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 109 (2004) 1212-1214
58. Lin Y., Tsuchihashi T., Matsumura K., Abe I., and Iida M. Central cardiovascular action of urotensin II in conscious rats. J Hypertens 21 (2003) 159-165
59. MacLean M.R., Alexander D., Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 130 (2000) 201-204
60. Mallamaci F., Cutrupi S., Pizzini P., Tripepi G., and Zoccali C. Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens 19 (2006) 505-510
61. Matsushita M., Shichiri M., Imai T., Iwashina M., Tanaka H., Takasu N., et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19 (2001) 2185-2190
62. Mori Y., Otabe S., Dina C., Yasuda K., Populaire C., Lecoeur C., et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51 (2002) 1247-1255
63. National Cholesterol Education Program. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
64. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
65. Onan D., Pipolo L., Yang E., Hannan R.D., and Thomas W.G. Urotensin-II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 (2004) 2344-2354
66. Ong K.L., Wong L.Y.F., Man Y.B., Leung R.Y.H., Song Y.Q., Lam K.S.L., et al. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance. Peptides 27 (2006) 1659-1667
67. Price J.F., Mowbray P.I., Lee A.J., Rumley A., Lowe G.D., and Fowkes F.G. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study. Eur Heart J 20 (1999) 344-353
68. Rajala M.W., and Scherer P.E. The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
69. Rdzanek A., Filipiak K.J., Karpinski G., Grabowski M., and Opolski G. Exercise urotensin II dynamics in myocardial infarction survivors with and without hypertension. Int J Cardiol 110 (2006) 175-178
70. Reaven G.M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
71. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
72. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
73. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
74. Santaniemi M., Kesaniemi Y.A., and Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 155 (2006) 745-750
75. Schmieder R.E., Hilgers K.F., Schlaich M.P., and Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007) 1208-1219
76. Sheridan M.A., Plisetskaya E.M., Bern H.A., and Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66 (1987) 405-414
77. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
78. Sidharta P.N., Wagner F.D., Bohnemeier H., Jungnik A., Halabi A., Krahenbuhl S., et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 80 (2006) 246-256
79. Silvestre R.A., Egido E.M., Hernandez R., Leprince J., Chatenet D., Tollemer H., et al. Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 151 (2004) 803-809
80. Silvestre R.A., Rodriguez-Gallardo J., Egido E.M., and Marco J. Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas. Horm Metab Res 33 (2001) 379-381
81. Sondermeijer B., Kompa A., Komesaroff P., and Krum H. Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension. Am J Hypertens 18 (2005) 1195-1199
82. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 (2004) H1597-H1602
83. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
84. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
85. Suguro T., Watanabe T., Ban Y., Kodate S., Misaki A., Hirano T., et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 (2007) 211-217
86. Sun H.X., Du W.N., Zuo J., Wu G.D., Shi G.B., Shen Y., et al. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 24 (2002) 223-227
87. Suzuki S., Wenyi Z., Hirai M., Hinokio Y., Suzuki C., Yamada T., et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25 (2004) 1803-1808
88. Thompson J.P., Watt P., Sanghavi S., Strupish J.W., and Lambert D.G. A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg 97 (2003) 1501-1503
89. Thompson P.D., Buchner D., Pina I.L., Balady G.J., Williams M.A., Marcus B.H., et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation 107 (2003) 3109-3116
90. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104 (2003) 1-5
91. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
92. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
93. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
94. Wang Y.X., Ding Y.J., Zhu Y.Z., Shi Y., Yao T., and Zhu Y.C. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 292 (2007) H348-H359
95. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
96. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19 (2001) 2191-2196
97. Watanabe T., Suguro T., Kanome T., Sakamoto Y., Kodate S., Hagiwara T., et al. Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages. Hypertension 46 (2005) 738-744
98. Watson A.M., Lambert G.W., Smith K.J., and May C.N. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 42 (2003) 373-379
99. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 112 (2003) 1785-1788
100. Wenyi Z., Suzuki S., Hirai M., Hinokio Y., Tanizawa Y., Matsutani A., et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46 (2003) 972-976
101. Wilkes J.J., Hevener A., and Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes 52 (2003) 1904-1909
102. Wilkinson I.B., Affolter J.T., de Haas S.L., Pellegrini M.P., Boyd J., Winter M.J., et al. High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 53 (2002) 341-347
103. Williams G., Bing C., Cai X.J., Harrold J.A., King P.J., and Liu X.H. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 74 (2001) 683-701
104. Yi L., Gu Y.H., Wang X.L., An L.Z., Xie X.D., Shao W., et al. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. J Int Med Res 34 (2006) 272-283
105. Zhu F., Ji L., and Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 82 (2002) 1473-1475
106. Zoccali C., Mallamaci F., Tripepi G., Cutrupi S., Pizzini P., and Malatino L. Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease. Kidney Int 69 (2006) 1253-1258
107. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 24 (2006) 611-619
108. Zou Y., Nagai R., and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508 (2001) 57-60